Rang	Name	Position
1	Dr. David Hallett Ph.D.	Chief Scientific Officer, Interim CEO, Principal Executive Officer & Executive Director
2	Mr. Ben R. Taylor	CFO, Chief Strategy Officer & Executive Director
3	Dr. John P. Overington Ph.D.	Chief Technology Officer
4	Ms. Sara Sherman	Vice President of Investor Relations
5	Mr. Dan Ireland	Executive VP of Legal & Company Secretary
6	Mr. Parker Moss	Executive Vice President of Corporate Development
7	Ms. Caroline Rowland	Chief People Officer
8	Mr. Richard Law	Chief Business Officer
9	Mr. Nikolaus Krall	Executive Vice President of Precision Medicine
10	Dr. Marie-Louise Helena Fjallskog M.D., Ph.D.	Interim Chief Medical Officer & Clinical Development Lead

Aufteilung der Investoren

Rang	Inhaber	Anteile	Wert
1	Novo A/S	10,00%	63,34 Mio. USD
2	SoftBank Group Corp	4,34%	27,50 Mio. USD
3	LAURION CAPITAL MANAGEMENT LP	3,42%	21,65 Mio. USD
4	Baillie Gifford & Co Limited.	2,94%	18,63 Mio. USD
5	Bill & Melinda Gates Foundation	1,22%	7,70 Mio. USD
6	MIC Capital Management UK LLP	1,18%	7,47 Mio. USD
7	Junked Platinum Investment Management Ltd	1,11%	7,05 Mio. USD
8	Goldman Sachs Group Inc	0,68%	4,31 Mio. USD
9	Pivotal bioVenture Partners Investment Advisor LLC	0,59%	3,73 Mio. USD
10	BlackRock Inc	0,54%	3,39 Mio. USD
11	Wells Fargo & Co	0,31%	1,97 Mio. USD
12	AllianceBernstein L.P.	0,29%	1,87 Mio. USD
13	Millennium Management LLC	0,24%	1,54 Mio. USD
14	Squarepoint Ops LLC	0,23%	1,46 Mio. USD
15	Jane Street Group LLC	0,22%	1,40 Mio. USD
16	Bank of New York Mellon Corp	0,21%	1,31 Mio. USD
17	Casdin Capital, LLC	0,16%	1,04 Mio. USD
18	Morgan Stanley - Brokerage Accounts	0,11%	0,68 Mio. USD
19	Yakira Capital Management, Inc.	0,10%	0,66 Mio. USD
20	HRT FINANCIAL LLC	0,10%	0,64 Mio. USD